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ARTICLE
MafB is a critical regulator of complement
component C1q
Mai Thi Nhu Tran1, Michito Hamada 1,2, Hyojung Jeon1, Risako Shiraishi1, Keigo Asano1, Motochika Hattori1,
Megumi Nakamura1, Yuki Imamura1, Yuki Tsunakawa1,3, Risa Fujii1, Toshiaki Usui1, Kaushalya Kulathunga1,3,
Christina-Sylvia Andrea4, Ryusuke Koshida1, Risa Kamei1, Yurina Matsunaga1, Makoto Kobayashi 4,
Hisashi Oishi5, Takashi Kudo1,2 & Satoru Takahashi1,2,6,7,8
The transcription factor MafB is expressed by monocytes and macrophages. Efferocytosis
(apoptotic cell uptake) by macrophages is important for inhibiting the development of
autoimmune diseases, and is greatly reduced in Mafb-deﬁcient macrophages. Here, we show
the expression of the ﬁrst protein in the classical complement pathway C1q is important for
mediating efferocytosis and is reduced in Mafb-deﬁcient macrophages. The efferocytosis
defect in Mafb-deﬁcient macrophages can be rescued by adding serum from wild-type mice,
but not by adding serum from C1q-deﬁcient mice. By hemolysis assay we also show that
activation of the classical complement pathway is decreased in Mafb-deﬁcient mice. In
addition, MafB overexpression induces C1q-dependent gene expression and signals that
induce C1q genes are less effective in the absence of MafB. We also show that Mafb-
deﬁciency can increase glomerular autoimmunity, including anti-nuclear antibody deposition.
These results show that MafB is an important regulator of C1q.
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MafB is a member of the large Maf transcription factorfamily, which includes basic-region leucine zipper typetranscriptional factors that bind to the Maf recognition
element (MARE) by dimerization1. MafB is expressed by, and is
important for the differentiation of, a variety of cell types, such as
pancreatic α and β cells, podocytes in the renal glomerulus, and
rhombomere r5 in the embryonic hindbrain, thymus, parathyroid
gland, and hair cuticles2–6. In haematopoietic cells, MafB is also
expressed selectively by monocytes and macrophages. Although
MafB is dispensable for macrophage differentiation3, 7, 8, MafB
inhibits foam cell apoptosis in atherosclerotic lesions by reducing
the expression of apoptosis inhibitor of macrophage (AIM)9,
indicating that MafB is important for the physiological properties
of macrophages and that it is possible MafB regulates macrophage
function in other diseases.
C1q binds to antigen-bound antibody molecules, leading to
activation of the classical complement pathway. C1q consists of
three subunits (C1qA, C1qB, and C1qC), and binds to a variety of
ligands and regulates biological and cellular responses through
two domains, the gC1q (globular head) region and the collagen-
like region10. C1q binds phosphatidylserine on early apoptotic
cells via gC1q and then prompts efferocytosis by macrophages.
Apoptotic cells are a source of self-antigen and lead to the pro-
duction of autoantibodies; therefore, C1qa-deﬁcient mice spon-
taneously develop systemic lupus erythematosus (SLE)-like
disease due to the accumulation of apoptotic cells11. Patients with
C1q deﬁciency also have >90% probability of developing SLE or
SLE-like autoimmune diseases. Homozygous C1q deﬁciency is
infrequent, but this trait is the strongest genetic risk factor for
SLE11–13. C1q expression is restricted primarily to macrophages
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Fig. 1Mafb-deﬁcient macrophages are unable to engulf apoptotic cells. a Apoptotic cell-induced expression of Mafb in both BMDMs and PMs.Mafb mRNA
was quantiﬁed by qRT-PCR; n= 4 for each group. The data were normalized to Hprt mRNA levels and are presented as the mean± s.e.m., *p< 0.05
compared with apoptotic cells (−AC) (Student’s t-test). The data are from one experiment representative of two independent experiments. b, c Jurkat
T cells were induced to apoptosis and labeled with CellTracker. Apoptotic cells were incubated with WT andMafb−/−macrophages. CD11b and CellTracker
double-positive populations represent macrophages that bind and/or engulf apoptotic cells. c The percentage of binding or uptake of apoptotic cells was
increased in a time-dependent manner in WT but not Mafb−/− (WT, n= 5; Mafb−/−, n= 6). d, e Apoptotic thymocytes were stained with pHrodo and
incubated with fetal liver-derived macrophages for 120min. e The percentage of cells that were taken up was signiﬁcantly reduced in Mafb−/−
macrophages (n= 5 for each group). g, h, f Peritoneal exudate cells (PECs) were analyzed by FACS after apoptotic thymocytes treated with pHrodo were
injected into the mice, which were injected with thioglycolate 3 days before. h The percentage of apoptotic cell uptake was signiﬁcantly reduced inMafb−/−
macrophages (WT, n= 4; Mafb−/−, n= 5). f Microscopic analysis showed that pHrodo ﬂuorescence was observed in the PECs of WT, but not Mafb−/−. c,
e, h Quantiﬁcation data are presented as the mean± s.e.m. *p< 0.05 compared with WT, (Student’s t-test). The data are from one experiment that was
representative of at least two independent experiments
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and immature dendritic cells (DC), and C1q in the serum is
supplied to a sufﬁcient degree by these cells, in contrast to other
complement components that are expressed by hepatocytes in the
liver14, 15. A C1q gene cluster (C1qa, C1qb, and C1qc) is present
in ~20-kb genomic regions and has synchronized expression, but
the molecular mechanism of this regulation is unknown16, 17.
Nuclear receptor transcription factors are involved in the
metabolic and immune activities of macrophages by regulating
target genes18. Liver X receptor (LXR) activation induces the
expression of Mertk and Gas6 and promotes apoptotic cell
clearance to suppress inﬂammatory pathways19. A deﬁciency in
RXRα, PPARγ, or PPARδ induces autoimmune kidney disease
due to the inhibition of complement C1q expression or other
apoptotic cell recognition factors20, 21. Our previous data showed
that the LXR/RXR directly regulates the expression of Mafb in
macrophages9. In the present study, we ﬁnd that the efferocytosis
ability is reduced in Mafb-deﬁcient macrophages, as are the
mRNA levels of C1qa, C1qb, and C1qc in Mafb-deﬁcient perito-
neal macrophages (PMs). Furthermore, activation of the classical
complement pathway is reduced in Mafb-deﬁcient mice, and
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Fig. 2 C1q gene expression is decreased in Mafb−/− macrophages. a Messenger RNAs of C1q genes in PMs were examined by qRT-PCR (n= 3 for each
group). b PMs of Mafbf/f::LysM-Cre and Mafbf/f were analyzed for the expression of the Mafb and C1q genes (n= 4 for each group). c A western blot
analysis was performed to measure C1q protein levels in the PMs of WT and Mafb−/−. The protein extracts were normalized to β-actin expression. The data
are from one experiment that was representative of at least two independent experiments. d The C1q genes were analyzed by qRT-PCR of macrophages and
immature DCs from WT or Mafb−/− (n= 4 for each group). The data are from one experiment that was representative of at least two independent
experiments. a, b, d The data were normalized to Hprt mRNA and are presented as the mean± s.e.m. *p< 0.05 compared with WT, **p < 0.01 (Student’s
t-test). e, f The hemolysis rates were analyzed using serum from fetal liver cell-transplanted mice 3 months after transplantation (e) or Mafbf/f::LysM-Cre
and control mice (8–10 weeks old) (f). The data were analyzed with the Mann–Whitney U-test, and the results from two independent experiments were
pooled. g A western blot analysis was performed to measure the C1q protein levels in the serum of 8-week-old WT andMafb−/−mice. Lower panel, the data
were normalized to the protein band of Ponceau S and are presented as the mean± s.e.m. **p< 0.01 compared with Mafbf/f (Student’s t-test). The data are
from one experiment that was representative of at least two independent experiments. h THP-1 cells were transfected with either control siRNA (si-control)
or MAFB siRNA (si-MAFB). The cells were stimulated with dexamethasone and IFNγ for 24 h after PMA stimulation. The data were normalized to HPRT
mRNA and are presented as the mean± s.e.m. n= 4 for each group. *p< 0.05 compared with si-control (Mafb, C1qa, C1qc, Student’s t-test; C1qb, Welch’s
t-test). The data are from one experiment that was representative of two independent experiments. i qRT-PCR was conducted using heterozygous
mafbb337/+ mutant zebraﬁsh. The data were normalized to csf1r mRNA and are presented as the mean± s.e.m. WT; n= 7, mafbb337/+; n= 6 for each group.
*p< 0.05 compared with WT (Student’s t-test). The data are from one experiment that was representative of two independent experiments
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these mice are susceptible to autoimmune-inducing conditions,
such as irradiation. By contrast, macrophage-speciﬁc Mafb con-
ditional knock-out mice have a weak autoimmune phenotype
under normal conditions. These results indicate that MafB is
important for the regulation of C1q gene expression and pro-
motes multiple C1q functions, such as inhibiting autoimmune
disease and promoting the classical pathway.
Results
MafB deﬁciency leads to defective efferocytosis by macro-
phages. Our previous microarray data revealed a nearly 50%
reduction in C1qa and C1qb expression (Supplementary Fig. 1)9.
Because several studies reporting a defect in C1q showed failed
apoptotic cell clearance, we hypothesized that a lack of MafB may
affect efferocytosis11, 22. First, we induced apoptosis in Jurkat cells
or thymocytes with dexamethasone, and then the apoptotic stage
was assessed using ﬂow cytometry with 7AAD and an anti-
Annexin V antibody. The early-apoptotic cells were positive for
Annexin V and negative for 7AAD (Supplementary Fig. 2A).
Next, to clarify the role of MafB in the efferocytosis by macro-
phages, we added early-apoptotic thymocytes to bone marrow-
derived macrophages (BMDMs) or PMs from WT mice, and we
found that Mafb expression was signiﬁcantly increased in both
types of macrophages (Fig. 1a). These data suggest that MafB
induction is involved in the macrophage response to apoptotic
cells. Next, we examined whether a lack of MafB affected the
phagocytosis of apoptotic cells. We added ﬂuorescent apoptotic
Jurkat cells to WT or Mafb−/− fetal liver-derived macrophages
and evaluated the ensuing phagocytosis by ﬂow cytometry. The
gating strategies are shown in Supplementary Fig. 3A–C. The
results showed that the numbers of Mafb−/− macrophages that
engulfed or bound the ﬂuorescent apoptotic cells were sig-
niﬁcantly reduced at 30, 60, and 120 min compared with WT
macrophages (Fig. 1b, c). We also examined whether Mafb−/−
PMs and resident macrophages had the same phenotype as Mafb
−/− fetal liver-derived macrophages. Because conventional Mafb-
deﬁcient mice die after birth, Mafb−/− and WT E14.5 fetal liver
cells were transplanted into X-ray-irradiated recipient mice
(8 weeks old) to generate hematopoietic-reconstituted mice.
Apoptotic cells were injected into the abdominal cavity of the
hematopoietic-reconstituted mice 2 months after transplantation.
A ﬂuorescence activated cell sorting (FACS) analysis performed
30 min after the injection of apoptotic thymocytes showed that
the resident and thioglycolate-elicited PMs from Mafb−/− mice
also failed to engulf or bind to ﬂuorescent apoptotic cells (Sup-
plementary Fig. 2C, D). To conﬁrm that Mafb-deﬁcient macro-
phages could neither bind to nor engulf apoptotic cells, we
monitored phagocytosis using pHrodo-succinimidyl ester
(pHrodo), which emits a ﬂuorescent signal that becomes brighter
in response to low pH (Supplementary Fig. 2B). After engulfment
of the pHrodo-labeled apoptotic thymocytes, the ﬂuorescent
signal of pHrodo could be detected because of the acidic envir-
onment in the phagosomes of macrophages. This method pre-
vents the detection of apoptotic cell binding on the surface of the
macrophages23. Flow cytometry data showed a signiﬁcantly
reduced phagocytic efﬁciency of Mafb−/− fetal liver-derived
macrophages (Fig. 1d, e) and PMs (Fig. 1g, h) compared with WT
macrophages. Using ﬂuorescence microscopy, we also observed
that the intensity of pHrodo light emission from WT PMs was
strong, whereas the signal intensity from the Mafb−/− macro-
phages was weak (Fig. 1f). These results demonstrate that MafB is
indispensable for a large proportion of the phagocytosis of
apoptotic cells by macrophages. By contrast, Mafb−/− macro-
phages could take up oxidized LDL and bacteria9, 24, indicating
that MafB deﬁciency speciﬁcally affects efferocytosis. In addition,
when we fed living thymocytes and ﬂuorescent beads individually
to WT or Mafb−/− macrophages, no difference was observed
between the phagocytosis performed by WT or Mafb−/− mac-
rophages (Supplementary Fig. 4A, B). This ﬁnding suggests that
MafB regulates the efferocytosis process.
MafB regulates C1q genes. Because the Mafb deﬁciency led to a
reduction in efferocytosis, we examined the expression of apop-
totic cell recognition factors in Mafb−/− macrophages by qRT-
PCR analysis. Consistent with the reduction in C1q our micro-
array results, the expression levels of C1qa, C1qb, and C1qc were
signiﬁcantly reduced in Mafb−/− fetal liver-derived macrophages
(8-fold decrease in C1qa; 2-fold decreases in C1qb and C1qc,
Supplementary Fig. 5A). A qRT-PCR analysis was performed
using peritoneal exudative macrophages from Mafb−/− fetal liver-
transplanted mice (20 weeks old), Mafbf/f::LysM-Cre mice
(8 weeks old), and age-matched control mice. The results showed
that the expression levels of C1qa, C1qb, and C1qc were decreased
7–10-fold in Mafb−/− PMs compared with the WT control
(Fig. 2a). We also generated Mafb conditional knock-out mice
(Mafbf/f) and crossed them with Mafbf/f and LysM-Cre knock-in
mice (Mafbf/f::LysM-Cre) speciﬁcally expressing Cre recombinase
in myeloid cells (Supplementary Fig. 6A, B). The expression of
C1q genes in the Mafbf/f::LysM-Cre PMs was also strongly
reduced (50-fold decrease in C1qa, 25-fold decrease in C1qb, and
100-fold decrease in C1qc), as was the expression of Mafb com-
pared with the control (Fig. 2b). Western blot analysis showed
that the C1q protein was also decreased in Mafb−/− and Mafbf/f::
LysM-Cre PMs compared with the control (Fig. 2c, full-length
uncropped blots are shown in Supplementary Fig. 7A, B). Next, to
examine the reduction in C1q gene expressions under physiolo-
gical conditions, donor (Ly5.1 congenic)-derived macrophages
(CD11b+CD45.1+) in Mafb−/−-transplanted mice were sorted by
FACS and analyzed by qRT-PCR. More than a 4–8-fold reduction
in C1q gene expression was observed in the spleen macrophages
of Mafb−/−-transplanted mice (Supplementary Fig. 5B). We also
evaluated the expression levels of Mfge8, Mertk, Tyro3, Axl, Tim-
4, and Itagv, which remained unchanged in Mafb−/− fetal liver-
derived macrophages (Supplementary Fig. 8A). Although the
expression levels of Gas6 and Itgb3 were signiﬁcantly decreased in
fetal liver-derived macrophages, there were no signiﬁcant changes
in the expression of Mfge8, Gas6, Itgαv or Itgb3 in Mafb−/− PMs
(Supplementary Fig. 8B). In peritoneal resident macrophages,
Tim-4 is a key protein in efferocytosis25. FACS data using an anti-
Tim-4 antibody revealed no change in Tim-4 expression between
WT and Mafb−/− macrophages (Supplementary Fig. 8C). These
results indicate that MafB regulates the C1q genes in macro-
phages from fetal liver, spleen, and peritoneal tissue.
Because previous reports have shown that immature DCs are
an additional source of C1q15, we induced immature DCs and
mDCs from E14.5 fetal liver cells with IL-4 and granulocyte
macrophage colony-stimulating factor (GM-CSF) in the presence
or absence of LPS and then performed qRT-PCR (Supplementary
Fig. 9A). Although Mafb expression tended to decrease upon DC
differentiation, C1q expression was diminished in both Mafb−/−
immature DCs (443-fold in C1qa, 661-fold in C1qb, 358-fold in
C1qc) and mDCs (36-fold in C1qa, 81-fold in C1qb, 53-fold in
C1qc) and in macrophages compared with WT (Supplementary
Fig. 9B, Fig. 2d). These results indicated that the Mafb deﬁciency
resulted in a reduction in the C1q gene expression in immature
DCs. The reduction in C1q in Mafb−/− was observed in
macrophages, immature DCs, and mDCs, suggesting that MafB
regulates the total C1q protein in the serum.
C1q is the ﬁrst activation protein to initiate the classical
complement pathway; therefore, we hypothesized that MafB is
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important for the classical complement pathway. To test this
hypothesis, we conducted a hemolysis assay. The results revealed
a 41% reduction in hemolysis in Mafb−/− serum compared with
WT (each mouse was 20 weeks old, Fig. 2e). Similarly, hemolysis
of Mafbf/f::LysM-Cre was decreased by 57% compared with
Mafbf/f (each mouse was 8–10 weeks old, Fig. 2f). Moreover, we
examined serum C1q protein levels by western blot analysis. The
results showed a 78% reduction in the protein levels of C1q in
Mafbf/f::LysM-Cre serum compared with the control (Fig. 2g, full-
length uncropped blots are shown in Supplementary Fig. 7C). To
summarize, MafB deﬁciency decreased the activity of the classical
complement pathway. These ﬁndings demonstrated that MafB is
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a key regulator of the classical complement pathway by regulating
C1q genes in macrophages and DCs.
We also assessed the regulation of C1Q genes by MAFB in
human macrophages. The human monocyte THP-1 cell line was
cultured and induced to differentiated into macrophages by using
phorbol myristate acetate (PMA). Although C1Q was not
expressed in the THP-1 macrophages, C1Q genes were strongly
induced by dexamethasone and IFNγ26. Under these conditions,
MAFB expression was also induced in addition to C1Q genes
(Supplementary Fig. 10). When MAFB expression was knocked
down by siRNA, the expressions levels of C1QA, C1QB, and
C1QC were signiﬁcantly decreased (50% decreased in MAFB, 66%
deceased in C1QA, 70% decreased in C1QB, 50% decreased in
C1QC, Fig. 2h).
In addition, we examined whether MafB could regulate C1q
expression in a lower vertebrate (zebraﬁsh). Zebraﬁsh also have
three c1q genes (zc1qa, zc1qb, and zc1qc), which seem to function
similarly to those in mammals27. To analyze the regulation of
zebraﬁsh c1q genes, we isolated RNA from adult tails of WT and
mafbb337/+, heterozygous MafB mutant ﬁsh with no DNA-
binding domain28, and we performed qRT-PCR. The results
indicated that the expression of all three c1q genes was decreased
in mafbb337/+ mutants (50% decrease in zc1qa, 62% decrease in
zc1qb, 63% decrease in zc1qc, Fig. 2i). Collectively, these ﬁndings
suggest that the MafB-dependent regulation of C1q genes in
macrophages is highly evolutionarily conserved among
vertebrates.
Because the expression of C1qa, C1qb, C1qc was strongly
decreased in Mafb-deﬁcient macrophages in vitro and in vivo,
and because our previous computational analysis study showed
that the C1qa promoter contains a MARE motif and is activated
by MafB overexpression29, we hypothesized that MafB regulates
all C1q genes by binding directly to the promoter. The sequences
of the C1qa, C1qb, and C1qc promoters were analyzed to identify
the putative transcription factor-binding sites for MafB. Notably,
the potential half-MARE sites were identiﬁed at −131 bp
upstream of the transcriptional initiation site of C1qa, −140 bp
upstream of the transcriptional initiation site of C1qb, and +24 bp
and +97 bp downstream of the transcriptional initiation site of
C1qc. All the potential half-MARE sites were highly conserved
among multiple mammalian species according to the UCSC
Genome Browser (http://genome.ucsc.edu/index.html) (Fig. 3a),
and they appeared to be conserved with respect to the C1q
promoters in zebraﬁsh (Fig. 3b). To evaluate the potential for
MafB to bind to this half-MARE, we constructed luciferase
reporter genes linked to the C1qa, C1qb, or C1qc promoters.
These constructs were co-transfected with a MafB expressing
vector into the RAW264.7 cell line. The results showed that the
MafB-expressing vector activated the C1qa, C1qb, and C1qc
promoters. Conversely, the C1qa −131/Luc mutant showed
decreased responsiveness to the MafB-expressing vector (Fig. 3c,
upper panel). On the C1qb promoter, the C1qb mut (−140)/Luc
reporter construct was not activated by MafB (Fig. 3c, middle
panel). On the C1qc promoter, both single mutants (at C1qc +24/
Luc and C1qc +97/Luc) showed decreased MafB-induced
activation of the C1qc promoter. However, MafB could not
activate the C1qc promoter with mutations (site 1: +97, site 2:
+24, Fig. 3c, lower panel). To conﬁrm direct MafB binding to
these half-MAREs, we conducted a chromatin immunoprecipita-
tion (ChIP) assay using the RAW 264.7 and human monocyte
THP-1 cell lines. The results obtained for the RAW264.7 cells
showed that MafB occupancy at these half-MAREs (C1qa: −131,
C1qb: −140, and C1qc: +24 and +97) was increased after the
transient transfection of the MafB expression vector in using anti-
Flag antibody (Fig. 3d). Moreover, the anti-MAFB antibody
detected endogenous MAFB occupancy, indicating direct binding
to the conserved half-MAREs of the C1QA, C1QB, and C1QC
promoters in dexamethasone-activated and IFNγ-activated
human THP-1 cells (Fig. 3e). Another C1QA half-MARE
(C1QA MARE 2, Fig. 3e) is not conserved in mice, and
anti-MAFB also detected MAFB binding in this half-MARE.
These results indicate that in both humans and mice, MafB
directly regulates C1qa, C1qb, and C1qc through the half-MARE
site.
Another Maf member, c-Maf, is also expressed in
macrophages. Notably, the expression of c-Maf was maintained
in Mafb−/− macrophages (Supplementary Fig. 11A). By
contrast, the expression of Mafb and C1qa in c-Maf−/−
macrophages was upregulated, suggesting that c-Maf could not
induce C1q expression (Supplementary Fig. 11B). Consistently,
the efferocytosis ability of c-Maf−/− macrophages seemed
to be increased (Supplementary Fig. 11C). We also examined
the expression of the C1q receptor (C1qRp) and another
complement component known as C3 and its receptor, CR1, in
Mafb-deﬁcient macrophages. The expression of C1qRp was not
reduced in Mafb−/− or Mafbf/f::LysM-Cre macrophages, while C3
and CR1 expression was slightly increased, suggesting a
compensatory effect of the decrease in C1q (Supplementary
Fig. 12A, B).
C1q rescues efferocytosis defect of Mafb-deﬁcient macro-
phages. Based on the above results, we hypothesized that the
efferocytosis defect in Mafb−/− macrophages may be caused by
the reduction in C1q gene expression. To test this hypothesis, we
rescued this defect using WT serum containing the C1q protein.
The results showed that 50 and 20% dilutions of WT serum with
medium rescued Mafb−/− efferocytosis in a dose-dependent
manner (Fig. 4a). The uptake of apoptotic cells by Mafb−/−
macrophages was improved in a time-dependent manner after the
addition of 50% diluted WT serum for 60 and 120 min (Fig. 4b).
Moreover, in heat-inactivated serum, the complement component
function was disrupted, and it could not improve the defect in
Mafb−/− efferocytosis (Fig. 4c). Furthermore, we used the serum
Fig. 3MafB directly regulates C1qa, C1qb, C1qc genes. a Half of the Maf recognition elements (half-MARE) were identiﬁed in C1q gene promoters using the
UCSC Genome Browser. The half-MARE site in the C1q gene promoters (bold) was highly conserved among mammalian species. b Half-MARE was also
conserved in zebraﬁsh. c A MafB-expressing vector was co-transfected with luciferase reporter constructs of C1qa, C1qb, or C1qc promoter containing a
MARE site or a mutant MARE site into RAW264.7 cells. The luciferase activity was analyzed after a 24 h transfection. The term “mut” indicates mutation in
the MARE sites. Data are presented as the means± s.e.m. of duplicates. The data are from one experiment that is representative of at least two
independent experiments. d A ChIP assay was conducted using RAW264.7 cells. Flag-mock and Flag-MafB-expressing vectors were transfected into the
cells. After 24 h, chromatin from the transfected cells was precipitated with anti-Flag and anti-IgG. The half-MARE sequences in the C1q gene promoters
were ampliﬁed and analyzed by qPCR. The data are from one experiment that was representative of at two independent experiments. e A ChIP assay was
conducted using THP-1 cells. The cells were collected after they were treated with or without dexamethasone (Dex) and IFNγ, and then chromatin was
precipitated with anti-MAFB and anti-IgG. The half-MARE sequences in the C1q gene promoters were ampliﬁed and analyzed by qPCR. The data are from
one experiment that was representative of two independent experiments
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from C1qa-deﬁcient mice. As expected, C1qa-deﬁcient serum was
also unable to rescue in the efferocytosis ability of Mafb−/−
macrophages (Fig. 4d). Finally, we examined whether puriﬁed
C1q could rescue the Mafb-deﬁcient macrophage phenotype. As
expected, the percentage of Mafb-deﬁcient macrophages with
apoptotic cells was signiﬁcantly increased in the presence of C1q
protein (Fig. 4e). The gating strategy of these data were shown in
Supplementary Fig. 2D–G. Overall, these data indicate that the
disruption of the efferocytosis ability of Mafb−/− macrophages is
caused by diminished C1q.
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Mafb-deﬁcient mice develop autoimmune disease. Because of
the lack of C1q in both mice and human that were induced to
have SLE-like autoimmune diseases11, 12, we examined whether
Mafb-deﬁcient mice developed an autoimmune phenotype. In
our fetal liver transplantation model, we used X-ray irradiation to
destroy the hematopoietic system. Ionizing radiation is known to
induce apoptosis30–32, and apoptotic cells induce autoimmune
disease30, 33, 34. Thus, we hypothesized that our transplanted
recipient mice would have autoantibodies. We assessed the levels
of anti-nuclear antibody (ANA) from 4 to 20 weeks after trans-
plantation (mice aged 12 weeks to 28 weeks). Negative and
positive signal of ANA titer is shown in Fig. 5a. Among the WT
transplanted mice, 63% had high ANA titers at 4 weeks after
transplantation. The ANA-positive samples then decreased in a
time-dependent manner (8 weeks, 36%, 20 weeks, 30%; Fig. 5b).
However, 52% of theMafb−/− transplanted mice had a high ANA
titer, and the percentage of mice with a signiﬁcantly higher ANA
titer remained at approximately 50% compared with WT
(4 weeks, 47%, 20 weeks, 53%; Fig. 5b). At 20 weeks after
transplantation, we also checked the titer range (1/160 to 1/2560).
The results indicated that the ANA titer of the Mafb−/− trans-
planted mice had signiﬁcantly increased (p= 0.0395, Fisher’s
exact test, Fig. 5b, c). ELISA data showed that more than half a
year after fetal liver transplantation (30–32 weeks old), the serum
levels of ANA and anti-dsDNA antibodies were signiﬁcantly
increased in Mafb−/− mice compared with the WT control mice
(Fig. 6a, b). We also collected kidneys from these mice and per-
formed periodic acid-Schiff (PAS) and Hematoxylin and Eosin
(H&E) staining. More than 20 cases of glomerulonephritis from
each genotype were observed and scored from 0 to 3 in a blinded
test (Supplementary Fig. 13)35. The data showed that the average
glomerulonephritis score of Mafb−/− mice (2.06) tended to be
higher than that of the WT control (1.46), suggesting that the
glomerulonephritis in Mafb−/− mice (34–38 weeks old) was
slightly higher developed than that in WT control mice (Fig. 6e).
Immunohistochemical staining of kidney sections showed that
the accumulation of immune complexes (IgG, IgM, and IgA) on
the glomeruli was higher in Mafb−/− mice than in WT mice
(55–60 weeks old) (Fig. 6f, g). Moreover, urinary protein excre-
tion in Mafb−/− mice was signiﬁcantly increased compared with
WT control mice (55–60 weeks old, p< 0.05, Welch’s t-test,
Fig. 6h). Conversely, the blood indices in Mafb−/− mice did not
differ from those of WT mice, indicating that MafB deﬁciency did
not affect hematopoietic cells (Supplementary Fig. 14). These
results indicate that conditions that induce autoantibodies, such
as X-ray irradiation, caused an accumulation of apoptotic cells
and that Mafb-deﬁcient mice may be more sensitive than the WT
control. In addition, 4-month-old Mafbf/f::LysM-Cre mice had
slightly but signiﬁcantly higher ANA and ds-DNA levels than did
control mice (Fig. 6c, d). A previous study showed that C1q
deﬁciency in a C57BL/6 genetic background did not show an
ANA titer and have a severe autoimmune phenotype36. Our
results are consistent with these ﬁndings because C57BL/6
background Mafbf/f::LysM-Cre mice showed a weak phenotype.
On the other hand, in autoimmunity-activated conditions, such
as the radiation-enhanced condition, autoimmune phenotype was
observed in Mafb−/−mice. Thus, it is possible that one of the
causes of the increased autoantibody levels inMafb-deﬁcient mice
was a reduction in C1q in serum.
MafB is a critical regulator of C1q-dependent gene expression.
Previous studies have shown that nuclear receptors, such as
PPARδ, RXRα, RAR, and LXRα, regulate C1q-dependent gene
expression and play roles in efferocytosis20, 21, 37. In particular,
PPARδ binds directly to the C1qb promoter region and activates
the expression of C1qb20. To compare C1q gene regulation
between MafB and PPARδ, we performed a luciferase assay of the
C1q promoters using a Mafb-expressing vector or a PPARδ/
RXRα-expressing vector complex. The Mafb-expressing vector
strongly induced the C1q promoters by approximately 40-fold
(C1qa), 400-fold (C1qb), and 100-fold (C1qc). Conversely, the
PPARδ/RXRα-expressing vector complex only induced a 2–3-fold
increase in the C1q promoters (Fig. 7a). These data indicate that
MafB can induce stronger activation of C1q promoters than
PPARδ.
To compare their ability to induce endogenous C1q genes, we
overexpressed Ppard/Rxra, Pparg/Rxra, Lxra/Rxra, Rxra, or Mafb
in RAW264.7 cells. The data showed that Mafb overexpression
strongly induced C1q-dependent gene expression, whereas
PPARδ, PPARγ, LXRα, and RXRα were either not induced or
were only slightly induced (Fig. 7b). Moreover, c-Maf expression
did not induce C1q-dependent gene expression (Fig. 7b),
conﬁrming the different functions of c-Maf and MafB. Taken
together, these data indicate that MafB plays a more prominent
role than other nuclear transcription factors in the induction of
C1q-dependent gene expression.
To determine whether these nuclear receptors (PPARδ,
PPARγ, LXRα, and RAR) form a genetic hierarchy with MafB
and C1q, we stimulated macrophages using agonists of PPARδ/
RXRα, LXRα/RXRα, and RAR/RXRα, and we analyzed the
expression of Mafb. Because previous studies have shown that
glucocorticoids and IFNγ can induce the expression of C1q16, 38,
we also stimulated macrophages with dexamethasone or IFNγ.
Mafb expression in macrophages was signiﬁcantly induced by
GW0742/9cRA, T1317/9cRA, ATRA, and dexamethasone. How-
ever, IFNγ did not induce the expression of Mafb (Fig. 7c). Next,
we identiﬁed whether MafB was necessary for the induction of
C1q expression by PPARδ/RXRα, LXRα/RXRα, RAR, dexa-
methasone, and IFNγ. Mafb-deﬁcient and control macrophages
were stimulated using GW0742 or T1317/9cRA for 16 h or with
ATRA, dexamethasone, or IFNγ for 24 h. C1q expression was
increased in both Mafb-deﬁcient and control macrophages after
stimulation with GW0742 (Fig. 7d). However, C1q-dependent
gene expression was signiﬁcantly lower in Mafb-deﬁcient
macrophages than in control macrophages. In contrast, T1317/
9cRA, ATRA, and dexamethasone did not induce C1q expression
in theMafb-deﬁcient macrophages, although C1qc expression was
increased following ATRA stimulation (Fig. 7d). These results
indicate that MafB is necessary for the regulation of C1q-
Fig. 4 C1q reduction causes defective efferocytosis by Mafb−/− macrophages. a Apoptotic Jurkat cells treated with CellTracker were incubated with Mafb
−/− fetal liver-derived macrophages in 0, 20, and 50% serum from WT mice (0%, n= 4; 20%, n= 3; 50%, n= 4). b Apoptotic Jurkat cells were incubated
with Mafb−/− macrophages with 50% WT serum and a different time course (n= 4 for each group). c Apoptotic Jurkat cells were incubated with or
without heat-inactivated serum or normal serum (serum-, n= 5; inactivated serum, n= 5; serum, n= 3). a–c The data are from one experiment that was
representative of at least two independent experiments. d Apoptotic Jurkat cells were incubated with Mafb−/− macrophages with or without C1q-deﬁcient
serum or WT serum (WT, n= 6; Mafb−/−, n= 10 for each sample). e Apoptotic Jurkat cells were incubated with Mafbf/f::LysM-Cre fetal liver-derived
macrophages that treated with or without 100 μg of puriﬁed human C1q 1 h before (Mafbf/f, n= 3; Mafbf/f::LysM-Cre, n= 10; Mafbf/f::LysM-Cre + C1q, n=
10). d, e The results are from two pooled independent experiments. a–e Quantiﬁcation data are presented as the mean± s.e.m.; **p< 0.01, n.s. not
signiﬁcant (a–e, Welch’s t-test)
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dependent gene expression in the nuclear receptor pathway. In
addition, PPARδ and IFNγ could induce low C1q-dependent
gene expression in the absence of MafB, whereas MafB was
necessary for C1q-dependent gene induction by LXRα/RXRα,
RAR, and dexamethasone. Overall, MafB is necessary for C1q-
dependent gene expression induced by nuclear receptor signaling.
Discussion
We investigated, for the ﬁrst time, whether MafB is an important
factor in the expression of C1qa, C1qb, and C1qc, which assemble
to form the C1q protein. C1q is the ﬁrst protein in the classical
complement pathway and is important for efferocytosis, which
inhibits the development of autoimmune disease. More recent
reports have shown that C1q binding to immune complexes also
affects the inﬂammatory properties of CD14dim monocytes, and
macrophages and DCs that have been polarized by C1q-late
apoptotic lymphocytes reduce allogeneic Th1 and Th17 cells39, 40.
These ﬁndings indicate that the prevention of autoimmune dis-
ease by C1q not only mediates efferocytosis but also regulates
inﬂammatory suppression in macrophages and DCs. Because of a
defect in these functions of C1q, C1qa-deﬁcient mice develop
autoimmune diseases11, 22. In addition, clinical reports from
around the world have shown that 90% of patients with C1q
mutations have autoimmune diseases, such as SLE12. Consistent
with these reports, we observed a similar phenotype in Mafb-
deﬁcient mice. A previous report showed that the primary source
of C1q is bone marrow-derived cells41, and C1q genes are pri-
marily expressed in macrophages and DCs15, 41, 42. Our results
showed that C1q expression was decreased in both macrophages
and DCs of Mafb-deﬁcient mice. Moreover, the impaired classical
pathway was observed because of decreased C1q protein in Mafb-
deﬁcient mouse serum. These results indicate that Mafb is
important for C1q production to prevent autoimmune disease
and enable innate immune responses.
According to data from microarray analyses of DC and mac-
rophage subsets,Mafb, C1qa, C1qb, and C1qc have been identiﬁed
as macrophage-speciﬁc genes43. These ﬁndings are consistent
with our results, which indicate that MafB has a strong correla-
tion with C1q expression. Therefore, we believe that MafB also
regulates C1q genes in other species. In human macrophage
THP-1 cells, knockdown of MAFB caused the downregulation of
C1Q genes (Fig. 2h). Moreover, in zebraﬁsh, c1q gene promoters
have half-MAREs (Fig. 3b), and mutation of mafb revealed a
reduction in c1q gene expression (Fig. 2i). Previous reports have
demonstrated the origin of the classical pathway in the sea lam-
prey44. We also discovered a half-MARE sequence in the 5′
upstream region of lamprey c1q-like genes. Therefore, the MafB
binding site may have contributed to the evolution of the more
primitive lectin pathway to the classical pathway that supports
adaptive immunity.
c-Maf, another large Maf transcription factor, is also expressed
in macrophages. In this study, increased expression of Mafb and
C1qa was observed in macrophage colony-stimulating factor (M-
CSF)-induced c-Maf-deﬁcient macrophages. Consistently, the
phagocytosis of apoptotic cells by c-Maf−/− macrophages was
increased compared with the WT control (Supplementary
Fig. 11A–C). Therefore, the increased expression of the C1qa gene
may be a secondary effect of c-Maf knock-out because of the
increased expression of Mafb. These data, together with our
previous results, demonstrate the different functions of MafB and
c-Maf3, 9, 45.
Several studies have investigated C1q gene promoters. In one
paper, the C1qb promoter was activated by IFNγ, and the C1qa
and C1qc promoters were suppressed. Results from a C1qb-
deletion mutant promoter identiﬁed regulatory sequences from
−141 to −9016. These data appear to be consistent with our results
showing a half-MARE in this region. Binding sites for IRF8 and
PU.1 were observed in this promoter region, suggesting interac-
tions between MafB and IRF8 or PU.1. However, further analyses
are required.
Our previous study showed that MafB promotes athero-
sclerosis by regulating AIM expression9. However, C1q also has
an important function in the inhibition of atherosclerosis. In early
atherosclerosis, apoptosis by macrophages was increased inMafb-
deﬁcient mice due to the reduction in AIM. Therefore, C1q may
not effect efferocytosis in this condition. However, in other
conditions, AIM also has multiple functions. It was recently
reported that AIM can enhance the complement cascade46.
Because both AIM and C1q bind to IgM, it is possible that AIM
may enhance both the classical pathway and the alternative
pathway during the development of hepatocellular carcinoma46,
47. AIM also inhibits obesity and ameliorates acute kidney injury,
which suggests that it functions in homeostasis in the body48, 49.
Because MafB regulates both AIM and C1q, MafB may be a
regulator of homeostasis.
Under atherogenic conditions, the nuclear receptor transcrip-
tion factor LXR regulates Mafb, which then regulates AIM9. In
the present study, we showed that PPARδ/RXRα, LXRα/RXRα,
RAR, or glucocorticoid receptor (GR) agonists could activate
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Fig. 5 ANAs are detected in serum from fetal liver transplanted Mafb−/−
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Mafb expression. This evidence indicates that sensor molecules,
which are members of the nuclear receptor family and include
LXRs, RXRα, RARα, PPARδ, and GR, control macrophage-
speciﬁc target genes by regulatingMafb. RXRs, which are partners
of LXRs and PPARs, are considered druggable targets because of
their functions in lipid metabolism and immunity. Although
selective RXR modulators have been identiﬁed, few drugs for
macrophage-associated diseases have been discovered because
RXRs have multiple functions in various cells50, 51. Selective
glucocorticoid receptor modulators have encountered similar
problems in drug development52. The present study showed that
the nuclear receptor-MafB-C1q pathway was macrophage-spe-
ciﬁc, which may facilitate the development of drugs for
macrophage-related pathologies, such as autoimmune disease and
atherosclerosis.
Methods
Mice. The Mafb−/− mice were generated with a 129/Sv background and back-
crossed to the C57BL/6J strain for seven or more generations3. The genotyping
primer sequences were described in previous studies3, 53. For hematopoietic
system-reconstituted mice, 5 × 106 fetal liver cells were isolated from E14.5 WT or
Mafb−/− (C57BL/6J-Ly5.1) embryos, and these cells were then injected into the tail
veins of lethally irradiated (7 Gy) 6-week-old WT (C57BL/6J-Ly5.2) mice. The
chimerism of the donor cells was determined based on Ly5.1+/(Ly5.1+ + Ly5.2+)
cell ratio. Mice with greater than 95% chimerism were used in further experiments.
For Mafb conditional knock-out mice, the Mafb gene was ﬂanked by a loxP ele-
ment with a neomycin-resistant gene using homologous recombination in C57BL/6
background ES cells54. These mice were then mated with mice expressing ﬂippase
(Supplementary Fig. 4)55. To deleteMafb speciﬁcally in the macrophage lineage, we
mated Mafbf/f mice with LysM-Cre mice (Jackson Laboratory, Bar Harbor, Maine,
USA) with its expression under the control of the endogenous Lys2 promoter56.
The mice were maintained under speciﬁc pathogen-free conditions in a laboratory
animal resource center at the University of Tsukuba. All experiments were per-
formed in compliance with relevant Japanese and institutional laws and guidelines
and were approved by the University of Tsukuba animal ethics committee
(authorization number 17–152).
Zebraﬁsh. AB strains were used as WT zebraﬁsh. The mafb knock-out line
mafbb337 was purchased from the Zebraﬁsh International Resource Center
(Eugene, OR, USA). The mafbb337 line has a single C-to-T point mutation in allele
337 that changes a glutamine codon to a stop codon and truncates the protein
upstream of the DNA-binding domain28. Because mafbb337 zebraﬁsh larvae die
between 6 and 9 days after fertilization57, we used a heterozygous mutant for the
analysis. After anesthetizing the animals with tricaine methanesulfonate (Nacalai,
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Fig. 6 Mafb−/− mice develop autoimmune disease. a ELISA analysis showed the ANA levels in serum from 6 to 12-month-old transplanted mice (WT,
n= 13; Mafb−/−, n= 9). b The production of anti-ds-DNA was observed in serum (n= 16 for each genotype). c The ANA level of Mafbf/f::LysM-Cre and
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n= 9). a–d The results of duplicate independent experiments were pooled. e Kidneys were stained with PAS and HE staining. Glomerulonephritis was
scored from 0 to 3 in a blinded test (WT, n= 16; Mafb−/−, n= 15). The data were analyzed with the Brunner–Munzel test. f The deposition of immune
complexes in glomeruli was assayed for the immune complex (IgG + IgM + IgA). g Immune complex-positive glomeruli were quantiﬁed (WT, n= 5;
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14805-82), we cut the tails of mafbb337 adults for the isolation of genomic DNA and
RNA for genotyping and qRT-PCR, respectively. For genotyping, genomic DNA
was ampliﬁed at the mutation sites by PCR using the speciﬁc primers listed in
Supplementary Table 1, and then it was digested with PvuII.
Apoptosis induction. To induce apoptotic thymocytes, we collected 1 × 108 thy-
mocytes from 5 to 7-week-old WT mice and cultured them in RPMI-1640 (Sigma)
medium containing 10% FBS, 1% penicillin/streptomycin, and dexamethasone
(0.07 μM) for 12 h. To induce apoptotic Jurkat cells, 1 × 107 Jurkat cells were
incubated in RPMI-1640 medium supplemented with 1% penicillin/streptomycin
and 50 μM etoposide (Sigma) for 16 h. Apoptotic cells were detected with a PE
Annexin V Apoptosis Detection Kit (BD, 559763).
In vitro apoptotic cell phagocytosis assay. We labeled apoptotic Jurkat cells with
5 μM CellTracker (Invitrogen) for 30 min at 37 °C. Labeled apoptotic thymocytes
and PMs were then mixed at a 1:1 apoptotic thymocyte:macrophage ratio and
incubated for 30, 60, and 120 min. Phagocytosis of the labeled apoptotic thymo-
cytes was then evaluated by ﬂow cytometry. To rescue the phagocytosis ability of
Mafb−/− macrophages, a mixture of apoptotic thymocytes and Mafb−/− PMs was
plated in cultured medium containing inactivated or activated serum or various
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concentrations of serum (0, 20, or 50%) for 0, 60, or 120 min. In addition, serum
from WT or C1qa−/− mice was used as a control for the rescue experiment. C1qa
−/− serum was kindly provided by Professor Marina Botto (Centre for Complement
and Inﬂammation Research, Imperial College, London). For the rescue experiment,
100 µg of puriﬁed human C1q (Complement Technology Inc.) was administered to
fetal liver-derived macrophages with 400 µl of DMEM/F12 medium in the presence
of M-CSF (10 ng ml−1) 1 h before the addition of CellTracker-labeled apoptotic
Jurkat cells. The cells were stained with antigen-presenting cell (APC)-conjugated
anti-mouse CD11b antibody (Clone: M1/70, eBiosciences), and ﬂow cytometry was
performed with LSR (Becton Dickinson); the results were analyzed with FlowJo
software (Treestar).
In vitro ﬂuorescent-bead phagocytosis assay. The 1-µm ﬂuorescent beads used
in this experiment were Nile red ﬂuorescent-conjugated carboxylate-modiﬁed
microspheres (Molecular Probes, F-8819). Macrophages were mixed with 0.05%
ﬂuorescent beads for 2 h, and the cells were washed three times with PBS. Pha-
gocytosis of the ﬂuorescent beads was evaluated by ﬂow cytometry with LSR
(Becton Dickinson) and analyzed with FlowJo software (Treestar).
In vivo apoptotic cell phagocytosis assay. Apoptotic thymocytes were incubated
with 20 ng ml−1 pHrodo (Invitrogen) for 1 h at 37 °C. Then, the labeled apoptotic
thymocytes were injected into the abdominal cavity of WT or Mafb−/− mice. After
30 min, PMs were collected and stained with APC-conjugated CD11b antibody,
and phagocytosis was assessed by ﬂow cytometry using LSR or a Biorevo ﬂuor-
escence microscope (KEYENCE).
To assess both resident and elicited PM populations, a FACS analysis was
performed using PE-conjugated anti-F4/80 antibody (Clone: Cl:A3-1, Adb
Serotec), APC-conjugated anti-CD11b antibody (Clone: M1/70, eBioscience), or
PE-conjugated anti-Tim-4 antibody (Biolegend).
Macrophage and DC culture. The mouse macrophage RAW264.7 cell line was
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with 10%
FBS and 1% penicillin/streptomycin9. For the overexpression experiment, 500 ng of
empty, MafB, c-Maf, PPARδ/RXRα, PPARγ/RXRα, LXRα/RXRα, and RXRα-
expressing vectors was transfected into RAW264.7 cells using the FuGENE6
transfection reagent (Promega) for 24 h. For the primary macrophage culture,
single-cell suspensions of fetal liver and bone marrow cells were prepared by
mechanical disruption (grinding with a syringe insert against a 70-mm nylon cell
strainer; BD Biosciences). Cells were re-suspended in DMEM supplemented with
10% FBS, 1% penicillin/streptomycin, and 10 ng ml−1 M-CSF (R&D Systems) and
then seeded onto tissue culture dishes. The culture medium was not changed for
the duration of the experiment. M-CSF (ﬁnal concentration, 10 ng ml−1) was added
every day from day 4 onwards9. To collect PMs, we injected thioglycolate into the
abdominal cavities of the mice for 4 days. Then, PBS was injected into the
abdominal cavities of the mice. The PBS was then collected and centrifuged at
1000 rpm for 4 min at 4 °C. The cell pellet was plated in cultured medium over-
night to remove any neutrophils (non-adherent cells). Resident macrophages were
collected without thioglycolate injection. Control (WT or Mafbf/f) and Mafb-
deﬁcient (Mafb−/− and Mafbf/f::LysM-Cre) macrophages were stimulated with
PPARδ agonist (100 nM GW0742 and 1 μM 9cRA) for 16 h; LXRα agonist (1 µM
T1317 and 1 µM 9cRA) for 12 h; or RAR agonist (1 µM ATRA and 1 µM 9cRA),
glucocorticoid (10 µM dexamethasone), 10 ng µl−1 IFNγ or vehicle for 24 h. For DC
culture, fetal liver monocytes were cultured in RPMI supplemented with 10% FBS,
1% penicillin/streptomycin, 10 ng ml−1 GM-CSF (R&D Systems, 415-ML) and 10
ng ml−1 interleukin (IL) 4 (Pepro Tech, 214-14). GM-CSF and IL4 were added to
the medium daily. For human macrophage cultures, human monocyte cell line
THP-1 cells were maintained in RPMI-1640 medium (Sigma, R8758) supple-
mented with 10% FBS and 1% penicillin/streptomycin. THP-1 monocytes were
treated with 16.2 nM phorbol 12-myristate 13-acetate (PMA) (Sigma, 79346) for
2 days to induce differentiation into macrophages. The PMA was then removed,
and the THP-1 macrophages were stimulated with 10 µM dexamethasone and 10
ng ml−1 IFNγ for 2 days.
ChIP and quantitative PCR. For mouse cells, a Flag-MafB-expressing vector was
transfected into RAW264.7 cells for 24 h using FuGENE6. For human samples,
THP-1 cells were differentiated into macrophages. Cells were ﬁxed with 1% for-
maldehyde for 8 min at room temperature. Then, fresh medium containing 200
mM glycine was added and incubated for 8 min at room temperature. The cells
were washed with PBS. Buffer NP-40 (10 mM Tris-HCl (pH 8.0), 10 mM NaCl, and
0.5% NP-40) was added, and the cells were collected. The cells were resuspended
and centrifuged at 1400 × g for 5 min at 4 °C with lysis buffer LB1 (50 mM HEPES
(pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-
100, and protease inhibitor), then lysis buffer LB2 (10 mM Tris-HCl (pH 8.0), 200
mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and protease inhibitor), and ﬁnally lysis
buffer LB3 (10 mM Tris-HCl (pH 8.0), 300 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 0.1% sodium deoxycholate, 0.5% N-lauryl sarcosine, and protease inhi-
bitor). The samples were sonicated to generate approximately 500-bp chromatin
fragments. Buffer LB3 containing 10% Triton X-100 was added to the samples,
which were then centrifuged at 15,000 rpm for 10 min at 4 °C. After the “input”
samples were separated, the supernatant was diluted in LB3 buffer and incubated
overnight with Dynabeads containing protein G conjugated to anti-IgG (Merck
Millipore), anti-Trimethyl-Histone H3 (Lys4) ChIP validated antibody (Merck
Millipore, 17–614) and anti-Flag antibodies (Sigma, F3165) for mouse samples, and
with anti-IgG (Merck Millipore), anti-Trimethyl-Histone H3 (Lys4) ChIP validated
antibody (Merck Millipore, 17–614) and anti-MAFB antibodies (P-20, Santa Cruz)
for human samples. Next, the immunoprecipitated samples were washed sequen-
tially with low-salt buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA,
0.1% SDS, and 1% Triton X-100), high-salt buffer (20 mM Tris-HCl (pH 8.0), 400
mM NaCl, 2 mM EDTA, 0.1% SDS, and 1% Triton X-100), RIPA buffer (50 mM
HEPES (pH 7.6), 500 mM LiCl, 1 mM EDTA, 1% NP-40, and 0.7% sodium
deoxycholate), and 50 mM NaCl buffer. The chromatin fragments were eluted from
the Dynabeads with elution buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, and
1% SDS) at 65 °C overnight. The samples were incubated with RNaseA and Pro-
tease K for 2 h at 55 °C to degrade the RNA and protein. The DNA was then
puriﬁed and used for quantitative PCR analysis. The “input” samples were used as
standard qPCR samples. The primer sequences were speciﬁc to the MARE sites of
the C1q promoters (Supplementary Table 1).
Quantitative RT-PCR analysis. Total RNA was collected using the Isogen kit
(Nippon Gene, 311-02501). cDNA was synthesized with a QuantiTect Reverse
Transcription Kit (Qiagen). The mRNA levels of mouse Mafb, C1qa, C1qb, C1qc,
PPARδ, Tim4, Gas6, Mfge8, Itgav, Itgb3, and MARCO; human MAFB, C1QA,
C1QB, and C1QC; and zebraﬁsh csf-1, mafb, c1qa, c1qb, and c1qc were examined
using SYBR green PCR master mix (Takara Bio). The mRNA levels were nor-
malized to the mouse Hprt or Gapdh or human HPRT mRNA level. The speciﬁc
primer sequences are listed in Supplementary Table 1.
Western blot analysis. PMs were lysed with RIPA buffer and then centrifuged at
15,000 rpm for 5 min at 4 °C. The supernatant was immunoblotted with anti-C1q
antibody (Abcam, Clone: 9A7, ab71089). For the serum analysis, the serum was
treated with the Qproteome Murine Albumin Depletion Kit (Qiagen). The samples
were immunoblotted with anti-C1q antibody (Abcam, Clone: 9A7, ab71089).
Hemolytic assay for C1q activity. Sheep red blood cells (SRBCs, Nisseizai,
10100002) were sensitized with anti-SBRC antibody (Denka Seiken, 430076) at a 1/
800 dilution to form Ab-sensitized SRBCs. Mouse serum was diluted 1/10 (for
hematopoietic system-reconstituted mice) or 1/50 (for conditional knock-out mice)
with GVB2+ (ionic Veronal-buffered saline containing 0.15 M Ca2+, 1 M Mg2+, and
1% gelatin). C1q-depleted human serum (Merck Millipore) was diluted 1/500.
Then, 100 µl of diluted mouse serum was incubated with 900 µl of C1q-depleted
serum and 400 µl of EA for 1 h at 37 °C. The mixture was then centrifuged at 2000
rpm for 10 min at 4 °C, and the supernatant was measured spectrophotometrically
at 541 nm.
Fig. 7MafB critically regulates C1q-dependent gene expression. a Activation of the C1q promoters by MafB or the PPARδ and RXRα complex was compared
using a luciferase assay. The data are from one experiment that was representative of two independent experiments. b Empty vector (mock), MafB, c-Maf,
PPARδ/RXRα, PPARγ/RXRα, LXRα/RXRα, or RXRα-expressing vectors were transfected into RAW264.7 cells. The expression ofMafb, C1qa, C1qb, and C1qc
was analyzed using qRT-PCR (n= 3 for each group). The data are from one experiment that was representative of at least two independent experiments. c
Control macrophages were treated with GW0742/9cRA (PPARδ/RXRα agonist), T1317/9cRA (LXRα/RXRα agonist), ATRA (RAR agonist),
dexamethasone (glucocorticoid), and INFγ. Mafb expression was analyzed using qRT-PCR (n= 3 for the GW0742, T1317/9cRA, ATRA, and
dexamethasone groups; n= 2 for IFNγ). d WT and Mafb−/− macrophages were stimulated with GW0742 or T1317/9cRA. Mafbf/f and Mafbf/f::Tie2-Cre
macrophages were stimulated with ATRA, dexamethasone or IFNγ. The expression of C1qa, C1qb, and C1qc was analyzed using qRT-PCR (n= 3 for the
GW0742, T1317/9cRA, ATRA, and dexamethasone groups; n= 2 for IFNγ). b–d The expression of target genes was normalized to Hprt mRNA. c, d The
data are presented as the mean± s.e.m. *WT vs. Mafb−/−, Mafbf/f vs. Mafbf/f::Tie2-Cre; # no treatment vs. agonist; *, #p< 0.05, **, ##p< 0.01, n.s. not
signiﬁcant (Student’s t-test)
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FACS analysis. To examine the transplanted mice for chimerism, peripheral blood
cells were isolated from WT and Mafb−/− mice. The cells were incubated with
antibody for 30 min. Anti-CD45.1 and anti-CD45.2 antibodies conjugated to APCs
or phycoerythrin (PE) (Anti-CD45.1, Clone: A20; Anti-CD45.2, Clone: 104, Bio-
Legend) were used in this experiment. Flow cytometry analysis was performed
using LSR (Becton Dickinson), and the results were analyzed with FlowJo software
(Treestar).
RNA interference. siRNAs of MAFB were synthesized with Stealth Select RNAi
(Invitrogen). The Stealth RNAi Negative Control (Invitrogen) was used as the
control. The siRNAs were transfected with RNAi Max (Invitrogen). The siRNA
and RNAi Max were mixed together at a 1:1 ratio. The mixture was then added to
the differentiated THP-1 cells at 2.5 × 105 cells/well. BLOCK-iT Alexa Fluor Red
Fluorescent Oligo (Invitrogen) was used to evaluate the transfection efﬁciency. The
siRNA sequences are listed in Supplementary Table 1.
Promoter analysis. The promoter regions of the C1q genes (C1qa, C1qb, and
C1qc) and the promoter region of the Mafb gene were analyzed with the UCSC
Genome Browser (https://genome.ucsc.edu/index.html). The 5.0 kb C1qa, 2.0 kb
C1qb, and −2000 bp to +200 bp C1qc promoters from genomic DNA of C57BL/6
mice were cloned into TOPO vectors and ampliﬁed individually. The C1q gene
promoters-TOPO vectors were isolated and puriﬁed with a Mini Prep kit (Invi-
trogen). The C1q gene promoters were ligated into a promoter-less luciferase
vector (pGL4.10, Promega) using KpnI and HindIII to generate luciferase reporter
gene constructs (C1qa/C1qb/C1qc promoter plasmids). C1qa/C1qb/C1qc mut
promoter plasmids were constructed from C1qa/C1qb/C1qc promoter plasmids
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) with the primers
described in Supplementary Table 1.
To examine whether MafB could activate the C1q promoters, the C1q promoter
vectors were co-transfected with the Mafb-expressing vector into RAW264.7 cells.
To compare the activation of C1q gene promoters under the stimulation of MafB
or PPARδ and RXRα, the C1q gene promoter vectors were co-transfected with
Mafb or PPARδ and an RXRα-expressing vector into RAW264.7 cells. The
transfection was performed using FuGENE6 transfection reagent (Promega). The
cells were then cultured for 24 h. The luciferase assay was performed with the Dual-
Luciferase Reporter Assay System (Promega). Brieﬂy, after transfection for 24 h, the
cells were lysed, and 20 μl of cell lysate was transferred to 100 μl of Luciferase Assay
Reagent II (LARII). The samples were then measured using a luminometer. A 100-
μl quantity of Stop&Glo reagent was added to the samples, and they were again
measured. The pRL-TK (Promega)-expressing vector was co-transfected into
RAW264.7 cells. A pRL-TK vector expressing Renilla reniformis luciferase was used
to normalize the transfection efﬁciency.
Autoimmunity in mice. For the ANA titer analysis, we used the FLUORO
HEPANA test (MBL). The anti-dsDNA antibody was evaluated using ELISA. An
HRP-conjugated rabbit anti-mouse IgG + IgA + IgM (H + L) antibody (Invitrogen,
61–6420) was used as the secondary antibody, and 3,3′,5,5′-tetramethylbenzidine-
hydrogen peroxide (TMP-H2O2, Thermo) was used as the substrate. Renal
pathology was assessed based on the glomerulonephritis level and the accumulation
of immune complexes in the glomeruli. Brieﬂy, ﬁxed kidneys were embedded in
parafﬁn or optimum cutting temperature compound to perform histological or
immunohistochemical staining, respectively. Parafﬁn sections were stained with
PAS or H&E and then analyzed by a blinded researcher. More than 20 glomeruli
from kidneys from each genotype were observed. The degree of glomerular lesion
was semiquantitatively estimated on a 0–3 scale, and the most frequent score from
the more than 20 glomeruli observed was adopted as the representative score of the
glomerular lesion (Supplementary Fig. 13)35. For the immunohistochemical
staining of glomeruli, 5-μm frozen sections were stained with rabbit anti-mouse
IgG + IgA + IgM antibody (Invitrogen, 61–6420). Multiple images at 100× mag-
niﬁcation were collected and combined to generate an entire kidney section using
Biorevo image analyzer software (Keyence). The stained glomeruli were then
counted. The average number of antibody-positive glomeruli from two kidneys/
mouse was normalized to the kidney area. Urinary albumin and creatinine were
analyzed using immunonephelometry and enzyme tests, respectively (Oriental
Yeast Co., Ltd). GraphPad Prism 5 (GraphPad Software) was used to analyze the
data.
Analysis of blood indices. Six months after transplantation, the blood from WT
or Mafb−/− mice was collected in tubes containing EDTA. The blood was imme-
diately analyzed using a Celltac-α automatic analyzer (NIHON KOHDEN, MEK-
6458).
Reagents. The agonists used in this study were as follows: GW0472 (Sigma);
T0901317 (T1317, Sigma); 9cRA (Sigma); dexamethasone (Sigma); ATRA (Sigma);
and IFNγ (R&D Systems).
Statistical analyses. All data were analyzed using the Shapiro–Wilk test for
normally distributed or non-normally distributed data. The data were also analyzed
using the F-test, Ansari–Bradley test, or Mood test to evaluate homoscedasticity or
heteroscedasticity. Parametric data analyzed with the Shapiro–Wilk test that were
found to be homoscedastic or heteroscedastic were analyzed with Student’s t-test or
Welch’s t-test, respectively. Non-parametric data that were homoscedastic or
heteroscedastic were analyzed with the Mann–Whitney U-test or Brunner–Munzel
test, respectively. All data were analyzed using R software (http://www.R-project.
org/).
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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